HeartBeam Soars 62% After FDA Breakthrough Designation for At-Home Heart Attack Test
BEAT sits 96% above its 52-week low of $0.355 on elevated volume (57× avg).
Summary
HeartBeam received FDA Breakthrough Device Designation for its 3D ECG system that assesses potential heart attacks at home. The designation was granted in under 30 days, faster than the standard 60-day window, and opens a path for expedited review and potential Medicare coverage upon clearance. Shares surged 62.43% to $0.71 on Monday, reflecting the market's reaction to this regulatory milestone. The company plans to design a multicenter pivotal study in the coming months, with patient enrollment to follow. This follows the earlier BusinessWire report of the designation, but the stock move is new information for traders.
At the time of this announcement, BEAT was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.3M. The 52-week trading range was $0.36 to $4.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.